Cargando…
A phase II dose-ranging study of mirabegron in patients with overactive bladder
INTRODUCTION AND HYPOTHESIS: Mirabegron is a potent and selective β(3)-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. METHODS: Patients completed a single-blinded, 2-week placebo run-in period followed by 12 w...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745617/ https://www.ncbi.nlm.nih.gov/pubmed/23471546 http://dx.doi.org/10.1007/s00192-013-2042-x |